Linsitinib (OSI-906) for the treatment of Adult and Pediatric Wild Type Gastrointestinal Stromal Tumors, a SARC Phase II study

PURPOSE: Most GISTs have activating mutations of KIT, PDGFRA, or uncommonly BRAF. Fifteen percent of adult and 85% of pediatric GIST are wild type (WT), commonly having high expression of IGF-1R and loss of succinate dehydrogenase (SDH) complex function. We tested the efficacy of linsitinib, an oral...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: von Mehren, Margaret, George, Suzanne, Heinrich, Michael C., Schuetze, Scott M., Yap, Jeffrey T., Yu, Jain Q., Abbott, Amanda, Litwin, Samuel, Crowley, John, Belinsky, Martin G., Janeway, Katherine A., Hornick, Jason L., Flieder, Douglas B., Chugh, Rashmi, Rink, Lori A., Van den Abbeele, Annick A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7856429/
https://ncbi.nlm.nih.gov/pubmed/31792037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1069
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados